Corporate Banner
Satellite Banner
Biomolecular Screening
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

GE Healthcare Launches Cytiva™ Plus Cardiomyocytes

Published: Wednesday, May 28, 2014
Last Updated: Wednesday, May 28, 2014
Bookmark and Share
GE’s most biologically relevant human cell model for improved compound safety profiling.

Identifying potential cardiotoxicity as early as possible in the drug development process can reduce the risk of costly program failures and minimize health risks. Cytiva™ Plus provides a high fidelity human heart cell model that is available in quantities compatible with screening, enabling earlier and more confident prioritization of compounds.

Conveniently cryopreserved in quantities to match a range of applications, Cytiva Plus cardiomyocytes are ready-for-use in multi-electrode arrays, impedance and high content analysis applications for compound safety profiling.

The cardiomyocytes are produced in a way that reflects native human heart cell development, without engineering techniques that could alter expression levels of relevant genes. This makes Cytiva Plus a dependable and reproducible biologically relevant cell model that supports the measurement of electrophysiological, structural and functional cell changes, and demonstrates expected pharmacological responses to reference compounds.

Compatible with diverse detection platforms, Cytiva Plus enables compound profiling based on multiple cardiotoxicity indications for more integrated risk assessment and mechanistic investigations, enabling better safety prediction.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,000+ scientific posters on ePosters
  • More than 4,500+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

GE Healthcare Life Sciences to Create New US Headquarters
When fully operational, the new facility will house more than 500 highly skilled employees and bring more than 220 new jobs to Massachusetts.
Wednesday, August 20, 2014
Spectacular Images Showing Research into Cancer, Neurodegenerative Disease and Fertility
Vanessa Auld from Canada, Martin Barr from Ireland and Graham Wright from Singapore announced as the winners of the GE Healthcare 2013 Cell Imaging Competition.
Wednesday, March 12, 2014
Scientific News
New Autism Blood Biomarker Identified
Researchers at UT Southwestern Medical Center have identified a blood biomarker that may aid in earlier diagnosis of children with autism spectrum disorder, or ASD.
It’s Now Easier To Go With The Flow
Rice University tool simplifies comparison of flow cytometry data for laboratories.
FNIH Launches Project to Evaluate Biomarkers in Cancer Patients
Company has announced that it has launched a new project to evaluate the effectiveness of liquid biopsies as biomarkers in colorectal cancer patients.
Drugs that May Combat Deadly Antibiotic-Resistant Bacteria Uncovered
Study identifies 79 compounds that inhibit carbapenem-resistant Enterobacteriaceae (CRE).
Making Precision Medicine a Reality
Researchers are one step closer to understanding the genetic and biological basis of diseases like cancer, diabetes, Alzheimer’s and rheumatoid arthritis – and identifying new drug targets and therapies.
Potential “Good Fat” Biomarker
New method to measure the activity of energy consuming brown fat cells could ease the testing weight loss drugs.
MicroRNA Pathway Could Lead to New Avenues for Leukemia Treatment
Cancer researchers at the University of Cincinnati have found a particular signaling route in microRNA (miR-22) that could lead to targets for acute myeloid leukemia, the most common type of fast-growing cancer of the blood and bone marrow.
Soy Shows Promise as Natural Anti-Microbial Agent
Soy isoflavones and peptides may inhibit the growth of microbial pathogens that cause food-borne illnesses, according to a new study from University of Guelph researchers.
Doubling Down on Dengue
HMS researchers have discovered two ways a compound blocks dengue virus.
Soy Shows Promise as Natural Anti-Microbial Agent
Researchers from University of Guelph show that soy isoflavones and peptides could be used to reduce microbial contamination of food.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,500+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!